{"id":"foy-305","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOY-305 directly inhibits Factor IIa (thrombin), a key serine protease in the blood coagulation cascade. By blocking thrombin activity, the drug reduces thrombin generation and fibrin formation, thereby preventing pathological blood clot formation. This mechanism is intended to provide anticoagulant effects for thrombotic disease prevention.","oneSentence":"FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:25.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombotic disorders (investigational)"}]},"trialDetails":[{"nctId":"NCT04321096","phase":"PHASE1, PHASE2","title":"The Impact of Camostat Mesilate on COVID-19 Infection","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2020-04-04","conditions":"Corona Virus Infection","enrollment":206},{"nctId":"NCT06794593","phase":"PHASE2","title":"Effect Camostat for Kidney Protection in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-21","conditions":"Chronic Kidney Disease(CKD)","enrollment":40},{"nctId":"NCT05474664","phase":"PHASE2","title":"Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2022-10-03","conditions":"Fontan Operation, Protein-Losing Enteropathy, Camostat Mesylate","enrollment":19},{"nctId":"NCT04470544","phase":"PHASE2","title":"Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Alan Bryce","startDate":"2020-07-28","conditions":"Severe Acute Respiratory Syndrome","enrollment":100},{"nctId":"NCT04625114","phase":"PHASE2","title":"The Potential of Camostat in COVID-19","status":"TERMINATED","sponsor":"University Hospital, Ghent","startDate":"2020-11-04","conditions":"Covid19","enrollment":108},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT04451083","phase":"PHASE1","title":"Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-07-01","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT04657497","phase":"PHASE3","title":"A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-11-09","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":155},{"nctId":"NCT04455815","phase":"PHASE2","title":"A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)","status":"TERMINATED","sponsor":"Cancer Research UK","startDate":"2020-09-23","conditions":"COVID-19 Infection","enrollment":34},{"nctId":"NCT04652765","phase":"PHASE1","title":"Camostat With Bicalutamide for COVID-19","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-02-03","conditions":"Covid19, SARS-CoV Infection, Coronavirus Infection","enrollment":6},{"nctId":"NCT04713176","phase":"PHASE3","title":"Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-02-02","conditions":"Severe COVID-19","enrollment":240},{"nctId":"NCT04662086","phase":"PHASE2","title":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-04-23","conditions":"Covid19","enrollment":122},{"nctId":"NCT04662073","phase":"PHASE2","title":"COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol","status":"TERMINATED","sponsor":"Stanford University","startDate":"2021-04-23","conditions":"Covid19","enrollment":2},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT04721535","phase":"PHASE3","title":"A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-06-07","conditions":"Covid19, SARS-COV-2 Infection","enrollment":9},{"nctId":"NCT04782505","phase":"PHASE1","title":"Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-03-12","conditions":"Healthy","enrollment":61},{"nctId":"NCT04730206","phase":"PHASE3","title":"The DAWN Antivirals Trial for Ambulatory COVID-19 Patients","status":"TERMINATED","sponsor":"KU Leuven","startDate":"2021-06-15","conditions":"Covid19, SARS-CoV Infection","enrollment":44},{"nctId":"NCT04521296","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo","status":"TERMINATED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-09-11","conditions":"Mild to Moderate COVID-19","enrollment":432},{"nctId":"NCT04524663","phase":"PHASE2","title":"Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-12-19","conditions":"Covid19","enrollment":49},{"nctId":"NCT04435015","phase":"PHASE1, PHASE2","title":"The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2021-11","conditions":"Coagulopathy, Cardiovascular Complication, COVID-19","enrollment":""},{"nctId":"NCT04353284","phase":"PHASE2","title":"Camostat Mesylate in COVID-19 Outpatients","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-06-09","conditions":"COVID-19","enrollment":70},{"nctId":"NCT04681430","phase":"PHASE2","title":"Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2021-01-08","conditions":"Corona Virus Infection, SARS-CoV-2 Infection, SARS-CoV-2 PCR Test Positive","enrollment":22},{"nctId":"NCT04608266","phase":"PHASE3","title":"CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-12-03","conditions":"Covid19","enrollment":70},{"nctId":"NCT04374019","phase":"PHASE2","title":"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Susanne Arnold","startDate":"2020-05-01","conditions":"COVID, Sars-CoV2","enrollment":13},{"nctId":"NCT04583592","phase":"PHASE2","title":"Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)","status":"COMPLETED","sponsor":"Sagent Pharmaceuticals Inc.","startDate":"2020-11-09","conditions":"COVID-19","enrollment":295},{"nctId":"NCT04750759","phase":"PHASE2","title":"Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat","status":"TERMINATED","sponsor":"Charité Research Organisation GmbH","startDate":"2021-02-03","conditions":"Covid19","enrollment":4},{"nctId":"NCT04644705","phase":"PHASE1","title":"Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat","status":"COMPLETED","sponsor":"Charité Research Organisation GmbH","startDate":"2020-11-02","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT04530617","phase":"PHASE2","title":"Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients","status":"TERMINATED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2020-10-05","conditions":"Covid19, Diabetes, Hypertension","enrollment":246},{"nctId":"NCT04338906","phase":"PHASE4","title":"Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","status":"WITHDRAWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2020-05","conditions":"COVID","enrollment":""},{"nctId":"NCT04355052","phase":"PHASE3","title":"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2020-04-11","conditions":"COVID - 19","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":84,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOY-305","genericName":"FOY-305","companyName":"Ono Pharmaceutical Co. Ltd","companyId":"ono-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOY-305 is a Factor IIa (thrombin) inhibitor that blocks the coagulation cascade to prevent thrombotic events. Used for Thrombotic disorders (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}